Diagnostic test combinations associated with thrombosis in lupus anticoagulant positive patients

• References

• 1 Devreese K, Hoylaerts MF. Challenges in the diagnosis of the antiphospholipid syndrome. Clin Chem 2010; 56: 930-940.
• 2 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
• 3 Pengo V, Ruffatti A, Legnani C. et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-242.
• 4 Pengo V, Biasiolo A, Pegoraro C. et al. Antibody pro-files for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-1152.
• 5 Ruffatti A, Tonello M, Del Ross T. et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006; 96: 337-341.
• 6 Galli M, Borrelli G, Jacobsen EM. et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110: 1178-1183.
• 7 van Os GM, Urbanus RT, Agar C. et al. Antiphospholipid syndrome. Current insights into laboratory diagnosis and pathophysiology. Hamostaseologie 2010; 30: 139-143.
• 8 Swadzba J, Iwaniec T, Szczeklik A. et al. Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases. J Thromb Haemost 2007; 5: 1883-1889.
• 9 de Laat B, Pengo V, Pabinger I. et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009; 7: 1767-1773.
• 10 Cervera R, Khamashta MA, Shoenfeld Y. et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68: 1428-1432.
• 11 Galli M, Reber G, de Moerloose P. et al. Invitation to a debate on the serological criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 399-401.
• 12 Pengo V. A contribution to the debate on the laboratory criteria that define the antiphospholipid syndrome. J Thromb Haemost 2008; 6: 1048-1049.
• 13 Swadzba J, Musial J. More on: the debate on anti-phospholipid syndrome classification criteria. J Thromb Haemost 2009; 7: 501-502 author reply 503–504.
• 14 Devreese K, Peerlinck K, Hoylaerts MF. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood 2010; 115: 870-878.
• 15 Brandt JT, Triplett DA, Alving B. et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anti-coagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
• 16 Devreese K, Peerlinck K, Arnout J. et al. Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography. Thromb Haemost 2009; 101: 185-196.
• 17 Decavele A-S, Schouwers S, Devreese K. Evaluation of three commercial ELISA kits for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol 2011; 33: 97-108.
• 18 Pierangeli SS, Harris EN. A protocol for determination of anticardiolipin antibodies by ELISA. Nat Protoc 2008; 3: 840-848.
• 19 Wong RC. Consensus guidelines for anticardiolipin antibody testing. Thromb Res 2004; 114: 559-571.
• 20 Forastiero R, Martinuzzo M, Pombo G. et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231-1238.
• 21 Naess IA, Christiansen SC, Cannegieter SC. et al. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006; 4: 44-49.
• 22 Runchey SS, Folsom AR, Tsai MY. et al. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol 2002; 119: 1005-1010.
• 23 Tarr T, Lakos G, Bhattoa HP. et al. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007; 16: 39-45.
• 24 Pengo V, Biasiolo A, Pegoraro C. et al. Antibody pro-files for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-1152.
• 25 Kaul M, Erkan D, Sammaritano L. et al. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis 2007; 66: 927-930.
• 26 Pourrat O, Jollit C, Gombert JM. et al. Clinical relevance of the recent update of the classification criteria for definite antiphospholipid syndrome: an obstetric medicine clinic series of 107 patients. J Thromb Haemost 2006; 4: 2276-2277.
• 27 de Moerloose P, Reber G, Musial J. et al. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost 2010; 16: 1540-1546.